Zobrazeno 1 - 10
of 384
pro vyhledávání: '"William E, Barlow"'
Autor:
Kristina A. Fanucci, Yalai Bai, Vasiliki Pelekanou, Zeina A. Nahleh, Saba Shafi, Sneha Burela, William E. Barlow, Priyanka Sharma, Alastair M. Thompson, Andrew K. Godwin, David L. Rimm, Gabriel N. Hortobagyi, Yihan Liu, Leona Wang, Wei Wei, Lajos Pusztai, Kim R. M. Blenman
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from p
Externí odkaz:
https://doaj.org/article/de40aac7a42e4da9b372c3f02f74cceb
Autor:
Kate K. Watabayashi, Ari Bell-Brown, Karma Kreizenbeck, Kathryn Egan, Gary H. Lyman, Dawn L. Hershman, Kathryn B. Arnold, Aasthaa Bansal, William E. Barlow, Sean D. Sullivan, Scott D. Ramsey
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Cancer Care Delivery (CCD) research studies often require practice-level interventions that pose challenges in the clinical trial setting. The SWOG Cancer Research Network (SWOG) conducted S1415CD, one of the first pragmatic clust
Externí odkaz:
https://doaj.org/article/218b102882d045bc8c10198da963e351
Autor:
Xiaotong Li, Sarah Warren, Vasiliki Pelekanou, Vikram Wali, Alessandra Cesano, Mingdong Liu, Patrick Danaher, Nathane Elliott, Zeina A. Nahleh, Daniel F. Hayes, Gabriel N. Hortobagyi, William E. Barlow, Christos Hatzis, Lajos Pusztai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast cancer is not well understood. Methods We analyzed pre- and post-treatment samples from 60 patients using the NanoString PanCancer IO360™
Externí odkaz:
https://doaj.org/article/3f7b7dd9132843928cd117cedf777461
Autor:
Corey W. Speers, W. Fraser Symmans, William E. Barlow, Alex Trevarton, Stephanie The, Lili Du, James M. Rae, Steven Shak, Rick Baehner, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobagyi, Daniel F. Hayes, Kathy S. Albain, Andrew Godwin, Alastair Thompson
Publikováno v:
Journal of Clinical Oncology. 41:1841-1848
PURPOSE Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined re
Autor:
Yuli Chen, William E. Barlow, Haojia Li, Cheng Lu, Andrew Janowczyk, German Corredor, Shridar Ganesan, Michael Feldman, Pingfu Fu, Hannah Gilmore, Kathy S. Albain, Lajos Pusztai, James Rae, Daniel Hayes, Andrew K. Godwin, Alastair M. Thompson, Anant Madabhushi
Publikováno v:
Cancer Research. 83:P2-11
Background: Lymph node (LN) involvement is a strong indicator of poor prognosis for breast cancer (BC), with adjuvant chemotherapy remaining fundamental to management of these patients. SWOG S8814 was a Phase III randomized trial of postmenopausal pa
Autor:
Irene Kang, Jamie K. Forschmiedt, Michelle M. Loch, William E. Barlow, Danika L. Lew, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Jieling Miao, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Publikováno v:
Cancer Research. 83:GS1-04
Introduction: Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the differential effect of endocrine therapy (ET) vs chemotherapy followed by endocrine therapy (CET), including the impact of menopausal st
Autor:
Laura M. Spring, William E. Barlow, Aditya Bardia, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky
Publikováno v:
Cancer Research. 83:HER2-19
Background: HER2 low breast cancer, defined as tumors with HER2 IHC expression 1+ or 2+ without HER2 gene amplification, represents a potential new therapeutic subgroup of metastatic breast cancer (BC). However, the clinical significance of HER2 low
Autor:
Marianna Chavez, Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz, Eleftherios (Terry) Mamounas, Soonmyung Paik, Hanna Bandos, Wajeeha Razaq, Anne O’Dea, Virginia Kaklamani, Andrea L.M. Silber, Lisa E. Flaum, Eleni Andreopolu, Joseph Baar, Albert G. Wendt, Jennifer F. Carney, Priyanka Sharma, Julie R. Gralow, Danika L. Lew, William E. Barlow, Gabriel N. Hortobagyi
Publikováno v:
Cancer Research. 83:GS1-07
BACKGROUND: Abnormalities of the PI3kinase/AKT/mTOR signaling network are common in breast cancer (BC) and are associated with endocrine resistance. Everolimus, an mTOR-inhibitor increased PFS when combined with endocrine therapy (ET) in the metastat
Autor:
Daniel Shao, William E. Barlow, Haojia Li, Cheng Lu, Kathy S. Albain, James Rae, Daniel F. Hayes, Andrew K. Godwin, Alastair M. Thompson, Anant Madabhushi, Lajos Pusztai
Publikováno v:
Cancer Research. 83:P2-11
Background: Adjuvant chemotherapy is a common treatment for breast cancer patients with aggressive tumors, but imposes severe side effects. Although lymph node involvement is associated with higher likelihood of mortality, a subset of LN+ patients ca
Autor:
Eve Rodler, Priyanka Sharma, William E Barlow, Julie R Gralow, Shannon L Puhalla, Carey K Anders, Lori Goldstein, Debu Tripathy, Ursa A Brown-Glaberman, Thu-Tam Huynh, Christopher S Szyarto, Andrew K Godwin, Harsh B Pathak, Elizabeth M Swisher, Marc R Radke, Kirsten M Timms, Danika L Lew, Jieling Miao, Lajos Pusztai, Daniel F Hayes, Gabriel N Hortobagyi
Publikováno v:
The Lancet Oncology. 24:162-174